Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All sotrovimab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchSotrovimabSotrovimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies

Zhou et al., bioRxiv, doi:10.1101/2022.02.15.480166
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Sotrovimab for COVID-19
40th treatment shown to reduce risk in May 2023
 
*, now known with p = 0.0017 from 22 studies, recognized in 38 countries. Efficacy is variant dependent.
Lower risk for hospitalization.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
In Vitro study showing that omicron BA.2 evades all monoclonal antibodies tested, including sotrovimab and tixagevimab/cilgavimab which retained activity for omicron BA.1.
Study covers sotrovimab, casirivimab/imdevimab, and bamlanivimab/etesevimab.
Zhou et al., 16 Feb 2022, preprint, 4 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperSotrovimabAll
Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies
Hao Zhou, Takuya Tada, Belinda M Dcosta, Ph.D Nathaniel R Landau
doi:10.1101/2022.02.15.480166
Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly successful in decreasing disease severity; however, the recent emergence of the heavily mutated Omicron variant has posed a challenge to this treatment strategy. The Omicron variant BA.1 has been found to evade neutralization by the Regeneron and Eli Lilly therapeutic monoclonal antibodies, while Sotrovimab and the Evusheld monoclonal
References
Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med
Cdc, Omicron Variant: What You Need to Know
Clinicaltrials, Gov, phase III Double-blind, Placebo-controlled Study of AZD7442
Group, Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial, Lancet Infect Dis
Li, Wang, Lavrijsen, Lamers, De Vries et al., SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination, Cell Research
Liu, Iketani, Guo, Chan, Wang et al., Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2, Nature
Lyngse, Kirkeby, Denwood, Christiansen, Mølbak et al., Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households, medRxiv
Majumdar, Sarkar, Mutational and phylogenetic analyses of the two lineages of the Omicron variant, J Med Virol
Noval, Mg, Kaczmarek, Koide, Rodriguez-Rodriguez et al., Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
Owen, Allerton, Anderson, Aschenbrenner, Avery et al., An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19, Science
Planas, Veyer, Baidaliuk, Staropoli, Guivel-Benhassine et al., Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization, Nature
Tada, Fan, Chen, Kaur, Stapleford et al., An ACE2
Tada, Zhou, Dcosta, Samanovic, Chivukula et al., Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies, bioRxiv
Vanblargan, Errico, Halfmann, Zost, Crowe et al., An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies, Res Sq
{ 'institution': [{'name': 'bioRxiv'}], 'indexed': {'date-parts': [[2022, 2, 16]], 'date-time': '2022-02-16T22:16:08Z', 'timestamp': 1645049768295}, 'posted': {'date-parts': [[2022, 2, 16]]}, 'group-title': 'Immunology', 'reference-count': 0, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'accepted': {'date-parts': [[2022, 2, 16]]}, 'abstract': '<jats:p>Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly ' 'successful in decreasing disease severity; however, the recent emergence of the heavily ' 'mutated Omicron variant has posed a challenge to this treatment strategy. The Omicron ' 'variant BA.1 has been found to evade neutralization by the Regeneron and Eli Lilly ' 'therapeutic monoclonal antibodies, while Sotrovimab and the Evusheld monoclonal antibody ' 'cocktail retain significant neutralizing activity. A newly emerged variant, Omicron BA.2, ' 'containing the BA.1 mutations plus an additional 6 mutations and 3 deletions, 3 of which lie ' 'in the receptor binding domain, has been found to be spreading with increased ' 'transmissibility. We report here, using a spike protein-pseudotyped lentivirus assay, that ' 'Omicron BA.2 is not neutralized with detectable titer by any of the therapeutic monoclonal ' 'antibodies, including Sotrovimab and the Evusheld monoclonal antibodies. The results ' 'demonstrate the difficulty of identifying broadly neutralizing monoclonal antibodies against ' 'SARS-CoV-2 and the importance of the T cell response from which immunoevasion is more ' 'difficult.</jats:p>', 'DOI': '10.1101/2022.02.15.480166', 'type': 'posted-content', 'created': {'date-parts': [[2022, 2, 16]], 'date-time': '2022-02-16T21:50:20Z', 'timestamp': 1645048220000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies'], 'prefix': '10.1101', 'author': [ {'given': 'Hao', 'family': 'Zhou', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0779-9954', 'authenticated-orcid': False, 'given': 'Takuya', 'family': 'Tada', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8497-4942', 'authenticated-orcid': False, 'given': 'Belinda M', 'family': 'Dcosta', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9997-1004', 'authenticated-orcid': False, 'given': 'Nathaniel R', 'family': 'Landau', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2022.02.15.480166', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 2, 16]], 'date-time': '2022-02-16T21:50:20Z', 'timestamp': 1645048220000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 2, 16]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1101/2022.02.15.480166', 'relation': {}, 'published': {'date-parts': [[2022, 2, 16]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit